Advances in PARP inhibitor use for metastatic breast cancer

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer

ECHO palliative care in Africa: Improving access to quality palliative care

Pembrolizumab increases long-term survival in patients with advanced NSCLC

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

ASCO 2019 and vision for cancer control

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma